pdb_id,structure_name,organism,resolution,space_group,crystal_system,unit_cell_a,unit_cell_b,unit_cell_c,unit_cell_alpha,unit_cell_beta,unit_cell_gamma,crystal_method,mean_bfactor,min_bfactor,max_bfactor,bfactor_range
5V39,Crystal structure of human vitamin D receptor ligand binding domain in complex with a VDRM,Homo sapiens,2.2,P 21 21 21,Orthorhombic,44.0,52.67,105.88,90.0,90.0,90.0,VAPOR DIFFUSION,21.54,5.79,94.99,89.2
6XZH,Structure of zVDR LBD-Calcitriol in complex with chimera 10,Danio rerio,2.372,P 65 2 2,Hexagonal,66.09,66.09,260.14,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",85.93,47.71,177.7,129.99
6XZI,Structure of zVDR LBD-calcitriol in complex with chimera 11,Danio rerio,2.1,P 65 2 2,Hexagonal,66.35,66.35,262.37,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",57.55,31.63,119.86,88.23
6XZJ,Structure of zVDR LBD-Calcitriol in complex with chimera 12,Danio rerio,2.1,P 65 2 2,Hexagonal,66.2,66.2,254.22,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",64.92,39.22,139.16,99.94
6XZK,Structure of zVDR LBD-Calcitriol in complex with chimera 13,Danio rerio,2.0,P 65 2 2,Hexagonal,66.112,66.112,262.488,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",48.89,27.0,109.56,82.56
6XZV,Structure of zVDR LBD-Calcitriol in complex with chimera 18,Danio rerio,2.3,P 65 2 2,Hexagonal,66.244,66.244,252.522,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",73.76,43.48,156.88,113.4
3B0T,Human VDR ligand binding domain in complex with maxacalcitol,Homo sapiens,1.3,P 21 21 21,Orthorhombic,45.013,51.377,132.121,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",15.89,8.93,35.08,26.15
7QPP,High resolution structure of human VDR ligand binding domain in complex with calcitriol,Homo sapiens,1.52,P 21 21 21,Orthorhombic,44.926,51.317,132.317,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",16.69,4.34,76.45,72.11
8PWD,Crystal structure of VDR in complex Des-C-Ring and Aromatic-D-Ring analog 3c,Danio rerio,2.8,P 65 2 2,Hexagonal,66.633,66.633,265.644,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",112.57,69.65,206.45,136.8
8PWE,Crystal structure of VDR complex with Novel Des-C-Ring and Aromatic-D-Ring analog 3a,Danio rerio,2.0,P 65 2 2,Hexagonal,65.8,65.8,263.387,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",49.17,24.79,113.89,89.1
8PWF,crystal structure of VDR in complex with Des-C-Ring and Aromatic-D-Ring analog 2,Danio rerio,2.3,P 65 2 2,Hexagonal,65.599,65.599,264.121,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",93.01,54.93,171.86,116.93
8PWM,Crystal structure of VDR in complex with Des-C-Ring and Aromatic-D-Ring analog 3b,Danio rerio,2.3,P 65 2 2,Hexagonal,65.849,65.849,264.213,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",90.76,30.0,160.04,130.04
8PZ6,"crystal structure of VDR in complex with D-Bishomo-1a,25-dihydroxyvitamin D3 analog 56",Danio rerio,2.9,P 65 2 2,Hexagonal,66.07,66.07,261.06,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",99.19,30.0,179.96,149.96
8PZ7,"crystal structure of VDR complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 57",Danio rerio,2.93,P 65 2 2,Hexagonal,66.24,66.24,264.04,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",81.63,30.0,140.5,110.5
8PZ8,"crystal structure of VDR in complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 54",Danio rerio,2.64,P 65 2 2,Hexagonal,65.37,65.37,262.01,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",79.46,44.32,169.43,125.11
8PZ9,"Crystal structure of VDR in complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 55",Danio rerio,2.74,P 65 2 2,Hexagonal,65.79,65.79,263.83,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",83.33,47.96,148.77,100.81
8PZB,"crystal structure of VDR in complex with D-Bishomo-1a,25-dihydroxyvitamin D3 Analog 49",Danio rerio,2.73,P 65 2 2,Hexagonal,65.62,65.62,263.62,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",78.36,30.0,133.67,103.67
9FW8,VDR complex with UG-650,Danio rerio,2.42,P 65 2 2,Hexagonal,66.01,66.01,264.2,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
1S0Z,Crystal structure of the VDR LBD complexed to seocalcitol.,Homo sapiens,2.5,P 21 21 21,Orthorhombic,45.134,52.528,132.648,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",23.05,1.35,73.98,72.63
1S19,Crystal structure of VDR ligand binding domain complexed to calcipotriol.,Homo sapiens,2.1,P 21 21 21,Orthorhombic,45.248,52.55,132.909,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",21.79,5.04,56.0,50.96
4IA1,Diastereotopic and Deuterium Effects in Gemini,Danio rerio,2.44,P 65 2 2,Hexagonal,65.893,65.893,266.886,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",59.24,32.29,105.92,73.63
4IA2,Diastereotopic and Deuterium Effects in Gemini,Danio rerio,2.95,P 65 2 2,Hexagonal,65.77,65.77,266.421,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",62.23,37.21,107.01,69.8
4IA3,Diastereotopic and Deuterium Effects in Gemini,Danio rerio,2.7,P 65 2 2,Hexagonal,66.044,66.044,266.634,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",52.69,25.97,99.0,73.03
4IA7,Diastereotopic and Deuterium Effects in Gemini,Danio rerio,2.7,P 65 2 2,Hexagonal,66.178,66.178,266.412,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",49.02,24.1,84.43,60.33
5YSY,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2R,3R)-5-[(E)-2-{(1R,3aS,7aR)-1-[(R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl}vinyl]-2-(3-hydroxypropyl)cyclohex-4-ene-1,3-diol",Homo sapiens,2.0,P 21 21 21,Orthorhombic,44.682,51.538,132.651,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",23.44,8.39,64.21,55.82
5YT2,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2S,3R)-5-[(E)-2-{(1R,3aS,7aR)-1-[(R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,6,7,7a-hexahydro-1H-inden-4-yl}vinyl]-2-(3-hydroxypropyl)cyclohex-4-ene-1,3-diol",Homo sapiens,2.0,P 21 21 21,Orthorhombic,44.565,51.565,132.49,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",25.75,10.64,69.09,58.45
9EZ1,"Vitamin D receptor in complex with 1,4a,25-trihydroxyvitamin D3",Danio rerio,1.95,P 65 2 2,Hexagonal,65.98,65.98,263.47,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9EZ2,"Vitamin D receptor complex with 1,4b,25-trihydroxyvitamin D3",Danio rerio,1.8,P 65 2 2,Hexagonal,66.14,66.14,263.74,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9GY8,Vitamin D Receptor complex with Sila-A,Danio rerio,2.2,P 65 2 2,Hexagonal,65.457,65.457,262.257,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9GYA,Vitamin D Receptor in complex with Sila-e,Danio rerio,1.85,P 65 2 2,Hexagonal,65.92,65.92,263.57,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9GYC,Vitamin D receptor in complex with Sila-d,Danio rerio,2.2,P 65 2 2,Hexagonal,65.914,65.914,262.944,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9GYJ,Vitamin D receptor in complex with Sila-c,Danio rerio,1.9,P 65 2 2,Hexagonal,65.745,65.745,262.744,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9GYK,Vitamin D receptor in complex with Sila-f,Danio rerio,2.2,P 65 2 2,Hexagonal,65.95,65.95,264.41,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
6T2M,VDR-ZK168281 complex,Danio rerio,3.0,P 65 2 2,Hexagonal,66.155,66.155,265.315,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",99.03,48.26,182.94,134.68
7OXZ,VDR complex with a side-chain hydroxylated derivative of lithocholic acid,Danio rerio,2.2,P 65 2 2,Hexagonal,66.38,66.38,263.186,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",53.79,21.07,136.35,115.28
7OY4,VDR complex of a side-chain hydroxylated derivatives of lithocholic acid,Danio rerio,2.0,P 65 2 2,Hexagonal,66.489,66.489,263.846,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",38.31,13.33,106.37,93.04
3CS4,Structure-based design of a superagonist ligand for the vitamin D nuclear receptor,Homo sapiens,2.0,P 21 21 21,Orthorhombic,45.007,51.37,132.236,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",23.29,6.69,78.01,71.32
3CS6,Structure-based design of a superagonist ligand for the vitamin D nuclear receptor,Homo sapiens,1.8,P 21 21 21,Orthorhombic,45.055,51.458,132.132,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",18.33,5.78,54.83,49.05
3M7R,Crystal structure of VDR H305Q mutant,Homo sapiens,1.8,P 21 21 21,Orthorhombic,44.402,51.67,131.888,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",16.65,3.4,43.79,40.39
4G2I,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Homo sapiens,1.8,P 21 21 21,Orthorhombic,44.741,51.449,132.427,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",19.16,6.06,48.58,42.52
5GT4,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2S,3R,5Z,7E,14beta,17alpha)-2-cyanopropoxy-9,10-secocholesta-5,7,10-triene-1,3,25-triol",Homo sapiens,1.83,P 21 21 21,Orthorhombic,44.663,51.842,131.475,90.0,90.0,90.0,EVAPORATION,20.14,7.78,103.91,96.13
8IQN,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 24,24-F2-25(OH)D3",Homo sapiens,1.639,P 21 21 21,Orthorhombic,45.02,51.434,132.375,90.0,90.0,90.0,VAPOR DIFFUSION,18.95,7.94,92.24,84.3
8IQT,Crystal structure of the human vitamin D receptor ligand binding domain complexed with (23R)-F-25(OH)D3,Homo sapiens,1.745,P 21 21 21,Orthorhombic,44.723,51.363,132.102,90.0,90.0,90.0,VAPOR DIFFUSION,27.46,13.01,82.37,69.36
5XPL,"Crystal structure of VDR-LBD complexed with 22S-butyl-25-hydroxyphenyl-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin D3",Rattus norvegicus,2.05,C 1 2 1,Monoclinic,128.78,44.91,45.52,90.0,93.62,90.0,"VAPOR DIFFUSION, HANGING DROP",26.41,11.25,81.41,70.16
1TXI,Crystal structure of the vdr ligand binding domain complexed to TX522,Homo sapiens,1.9,P 21 21 21,Orthorhombic,45.259,52.504,132.93,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",19.93,5.74,49.97,44.23
2HAM,Crystal structure of VDR LBD complexed to 2alpha-propyl-calcitriol,Homo sapiens,1.9,P 21 21 21,Orthorhombic,45.06,51.326,131.304,90.0,90.0,90.0,"VAPOR DIFFUSION, SITTING DROP",24.68,9.7,68.96,59.26
2HAR,Crystal structure of VDR LBD in complex with 2 alpha-(3-hydroxy-1-propoxy) calcitriol,Homo sapiens,1.9,P 21 21 21,Orthorhombic,45.118,51.318,131.284,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",25.53,11.34,74.78,63.44
2HAS,Crystal structure of VDR LBD in complex with 2alpha-(1-propoxy) calcitriol,Homo sapiens,1.96,P 21 21 21,Orthorhombic,45.1,51.669,131.715,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",26.76,10.87,79.06,68.19
2HB7,Crystal structure of VDR LBD in complex with 2alpha(3-hydroxy-1-propyl) calcitriol,Homo sapiens,1.8,P 21 21 21,Orthorhombic,44.981,51.368,132.201,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",24.28,9.4,81.76,72.36
2HB8,Crystal structure of VDR LBD in complex with 2alpha-methyl calcitriol,Homo sapiens,2.0,P 21 21 21,Orthorhombic,44.99,51.56,132.21,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",19.88,4.46,81.37,76.91
3A2I,Crystal structure of the human vitamin D receptor (H305F) ligand binding domain complexed with TEI-9647,Homo sapiens,3.27,P 21 21 21,Orthorhombic,44.796,51.365,131.773,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",20.59,2.74,38.69,35.95
3A2J,Crystal structure of the human vitamin D receptor (H305F/H397F) ligand binding domain complexed with TEI-9647,Homo sapiens,2.7,P 21 21 21,Orthorhombic,44.687,51.393,131.846,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",21.91,6.94,41.57,34.63
3AUQ,Crystal structure of the human vitamin D receptor ligand binding domain complexed with Yne-diene type analog of active 14-epi-2alpha-methyl-19-norvitamin D3,Homo sapiens,2.64,P 21 21 21,Orthorhombic,44.313,52.108,132.577,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",42.93,29.69,63.32,33.63
3AUR,Crystal structure of the human vitamin D receptor ligand binding domain complexed with Yne-diene type analog of active 14-epi-2beta-methyl-19-norvitamin D3,Homo sapiens,2.21,P 21 21 21,Orthorhombic,44.279,51.44,131.985,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",34.61,17.2,77.42,60.22
3AX8,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 15alpha-methoxy-1alpha,25-dihydroxyvitamin D3",Homo sapiens,2.6,P 21 21 21,Orthorhombic,44.489,51.585,132.017,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",15.92,2.0,53.83,51.83
3AZ1,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.5,P 21 21 21,Orthorhombic,44.613,51.732,131.579,90.0,90.0,90.0,hanging drop,30.57,14.86,97.47,82.61
3AZ2,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.69,P 21 21 21,Orthorhombic,44.53,51.84,132.4,90.0,90.0,90.0,hanging drop,24.73,10.75,78.4,67.65
3AZ3,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.36,P 21 21 21,Orthorhombic,44.32,52.222,131.946,90.0,90.0,90.0,hanging drop,25.33,11.65,80.3,68.65
3O1D,"Structure-function study of Gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097.",Danio rerio,2.4007,P 65 2 2,Hexagonal,66.108,66.108,264.64,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",60.12,26.42,392.64,366.22
3O1E,"Structure-function of Gemini derivatives with two different side chains at C-20, Gemini-0072 and Gemini-0097.",Danio rerio,2.5001,P 65 2 2,Hexagonal,65.842,65.842,263.718,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",66.83,24.51,578.69,554.18
3P8X,"Synthesis, Structure, and Biological Activity of des-Side Chain Analogues of 1alpha,25-Dihydroxyvitamin D3 with Substituents at C-18",Homo sapiens,1.7,P 21 21 21,Orthorhombic,44.628,51.342,130.82,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",19.25,0.0,50.72,50.72
3VHW,Crystal structure of the human vitamin D receptor ligand binding domain complexed with 4-MP,Homo sapiens,2.43,P 21 21 21,Orthorhombic,44.975,51.47,131.264,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",23.21,5.99,67.39,61.4
3W0A,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.8,P 21 21 21,Orthorhombic,44.619,51.803,132.513,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",26.33,10.51,95.62,85.11
3W0C,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.9,P 21 21 21,Orthorhombic,44.37,51.917,132.087,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",24.74,5.66,88.76,83.1
3W0Y,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,1.98,P 21 21 21,Orthorhombic,45.217,51.124,132.664,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",28.01,12.22,98.71,86.49
3WWR,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1-((((1S,2R,6R,Z)-2,6-dihydroxy-4-((E)-2-((1R,3aS,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-3-methylenecyclohexyl)oxy)methyl)cyclopropanecarbonitrile",Homo sapiens,3.18,P 21 21 21,Orthorhombic,45.167,51.826,132.384,90.0,90.0,90.0,VAPOR DIFFUSION,49.0,35.55,68.21,32.66
3X31,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 7,8-cis-14-epi-1a,25-Dihydroxy-19-norvitamin D3",Homo sapiens,2.11,P 21 21 21,Orthorhombic,44.369,51.508,131.52,90.0,90.0,90.0,VAPOR DIFFUSION,31.72,13.94,115.33,101.39
3X36,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 7,8-cis-1a,25-Dihydroxy-19-norvitamin D3",Homo sapiens,1.93,P 21 21 21,Orthorhombic,44.819,51.27,132.166,90.0,90.0,90.0,VAPOR DIFFUSION,18.91,6.24,133.39,127.15
4FHH,Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition,Danio rerio,2.33,P 65 2 2,Hexagonal,66.289,66.289,264.225,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",53.04,26.78,96.5,69.72
4ITE,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1alpha,25-Dihydroxy-2alpha-[2-(2H-tetrazol-2-yl)ethyl]vitamin D3",Homo sapiens,2.49,P 21 21 21,Orthorhombic,44.76,51.531,131.781,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",21.23,5.22,57.39,52.17
4ITF,"Crystal structure of the human vitamin D receptor ligand binding domain complexed with 1alpha,25-Dihydroxy-2alpha-[2-(1H-tetrazole-1-yl)ethyl]vitamin D3",Homo sapiens,2.84,P 21 21 21,Orthorhombic,44.353,51.809,132.08,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",28.07,8.81,59.7,50.89
4Q0A,Vitamin D Receptor complex with lithocholic acid,Danio rerio,1.9,P 65 2 2,Hexagonal,66.213,66.213,262.571,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",43.42,27.83,85.72,57.89
4RUO,Crystal structure of zVDR L337H mutant-gemini complex,Danio rerio,2.805,P 65 2 2,Hexagonal,66.085,66.085,265.233,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",67.39,22.35,230.34,207.99
5LGA,"Structural analysis and biological activities of BXL0124, a Gemini analog of Vitamin D",Danio rerio,2.5,P 65 2 2,Hexagonal,65.86,65.86,263.83,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",104.61,47.51,205.08,157.57
8P9X,Vitamin D receptor complex with Xe4Me agonist ligand,Danio rerio,2.15,P 65 2 2,Hexagonal,65.827,65.827,264.258,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",76.49,30.0,155.64,125.64
7QPI,"Structure of lamprey VDR in complex with 1,25D3",Petromyzon marinus,2.5,P 21 21 21,Orthorhombic,37.32,66.17,105.69,90.0,90.0,90.0,"VAPOR DIFFUSION, SITTING DROP",36.62,11.82,102.58,90.76
7OXU,VDR complex - calcitroic acid,Danio rerio,2.39,P 65 2 2,Hexagonal,65.728,65.728,264.354,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",62.11,28.92,148.24,119.32
4G1D,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.9,P 65 2 2,Hexagonal,66.287,66.287,263.662,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",52.2,11.27,118.91,107.64
4G1Y,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.85,P 65 2 2,Hexagonal,65.559,65.559,263.876,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",66.31,36.77,109.14,72.37
4G1Z,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.5,P 65 2 2,Hexagonal,66.472,66.472,262.336,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",73.11,41.75,115.53,73.78
4G20,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.9,P 65 2 2,Hexagonal,66.497,66.497,262.551,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",60.85,25.16,109.1,83.94
4G21,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.9,P 65 2 2,Hexagonal,66.287,66.287,263.662,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",63.47,37.02,103.07,66.05
4G2H,Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear Receptor,Danio rerio,2.5,P 65 2 2,Hexagonal,66.438,66.438,265.761,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",56.57,30.94,97.17,66.23
5E7V,Potent Vitamin D Receptor Agonist,Danio rerio,2.4,P 65 2 2,Hexagonal,66.49,66.49,263.34,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",62.65,35.14,170.02,134.88
5MX7,"1a,20S-dihydroxyvitamin D3 VDR complex",Danio rerio,1.98,P 65 2 2,Hexagonal,65.936,65.936,262.97,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
5OW7,VDR complex,Danio rerio,2.1,P 65 2 2,Hexagonal,65.699,65.699,262.259,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",41.15,12.2,138.37,126.17
7BNS,VDR complex with BXL-62,Danio rerio,2.7,P 65 2 2,Hexagonal,65.874,65.874,263.683,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
7BNU,VDR complex with BXL-62,Danio rerio,2.4,P 65 2 2,Hexagonal,65.658,65.658,264.139,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
7BO6,VDR complex with LCA derivative,Danio rerio,2.86,P 65 2 2,Hexagonal,66.39,66.39,263.82,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",94.24,30.0,187.08,157.08
7ZFG,VDR complex with aromatic D-ring analog,Danio rerio,2.62,P 65 2 2,Hexagonal,65.83,65.83,264.92,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",83.02,47.63,154.7,107.07
7ZFX,VDR complex with Aromatic-D-Ring Analog,Danio rerio,2.6,P 65 2 2,Hexagonal,65.723,65.723,263.897,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",67.46,30.0,138.71,108.71
8CK5,"VDR LBD complex with 25-nitro derivative of 1,25D3",Danio rerio,2.1,P 65 2 2,Hexagonal,65.701,65.701,262.106,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",63.39,31.49,128.27,96.78
9EYR,VDR complex with gemini analog UG-480,Danio rerio,2.56,P 65 2 2,Hexagonal,65.67,65.67,263.73,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
9FBF,VDR complex with UG-481,Danio rerio,3.01,P 65 2 2,Hexagonal,65.54,65.54,262.95,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",,,,
2ZL9,"2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure",Rattus norvegicus,1.9,C 1 2 1,Monoclinic,153.902,42.32,42.13,90.0,95.67,90.0,"VAPOR DIFFUSION, HANGING DROP",42.28,20.72,81.69,60.97
2ZLA,"2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure",Rattus norvegicus,2.0,C 1 2 1,Monoclinic,153.985,42.002,42.152,90.0,95.77,90.0,"VAPOR DIFFUSION, HANGING DROP",38.91,20.86,76.94,56.08
2ZLC,"2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure",Rattus norvegicus,2.0,C 1 2 1,Monoclinic,153.859,41.998,41.951,90.0,96.06,90.0,"VAPOR DIFFUSION, HANGING DROP",39.96,17.58,83.92,66.34
3VT4,Crystal structures of rat VDR-LBD with R270L mutation,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,153.725,41.865,42.217,90.0,95.92,90.0,"VAPOR DIFFUSION, HANGING DROP",39.9,19.51,84.32,64.81
3VT5,Crystal structures of rat VDR-LBD with R270L mutation,Rattus norvegicus,2.11,C 1 2 1,Monoclinic,153.174,42.565,42.184,90.0,96.1,90.0,"VAPOR DIFFUSION, HANGING DROP",52.9,25.61,100.53,74.92
3VT6,"Crystal structure of rat VDR-LBD with 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3",Rattus norvegicus,2.3,C 1 2 1,Monoclinic,153.734,42.724,42.271,90.0,95.55,90.0,"VAPOR DIFFUSION, HANGING DROP",48.19,18.22,108.32,90.1
3VT8,Crystal structures of rat VDR-LBD with W282R mutation,Rattus norvegicus,2.1,C 1 2 1,Monoclinic,155.068,42.052,41.868,90.0,95.62,90.0,"VAPOR DIFFUSION, HANGING DROP",33.28,10.58,92.88,82.3
3VT9,Crystal structures of rat VDR-LBD with W282R mutation,Rattus norvegicus,2.35,C 1 2 1,Monoclinic,154.714,42.05,41.972,90.0,95.63,90.0,"VAPOR DIFFUSION, HANGING DROP",34.64,8.34,91.84,83.5
3A40,Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277B(C23R),Homo sapiens,1.45,P 21 21 21,Orthorhombic,44.969,51.496,131.91,90.0,90.0,90.0,"VAPOR DIFFUSION, SITTING DROP",15.67,8.04,40.87,32.83
3KPZ,"Crystal structure of a novel vitamin D3 analogue, ZK203278 showing dissociated profile",Homo sapiens,1.9,P 21 21 21,Orthorhombic,44.887,51.892,132.204,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",20.01,6.96,48.25,41.29
3OGT,"Design, Chemical synthesis, Functional characterization and Crystal structure of the sidechain analogue of 1,25-dihydroxyvitamin D3.",Homo sapiens,1.75,P 21 21 21,Orthorhombic,45.018,51.622,132.818,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",13.68,1.91,125.4,123.49
3TKC,"Design, Synthesis, Evaluation and Structure of Vitamin D Analogues with Furan Side Chains",Homo sapiens,1.75,P 21 21 21,Orthorhombic,45.018,51.622,132.818,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",14.08,5.13,123.53,118.4
3WGP,Crystal Structure Analysis of Vitamin D receptor,Homo sapiens,2.0,P 21 21 21,Orthorhombic,44.82,51.39,131.64,90.0,90.0,90.0,,25.06,10.93,97.05,86.12
3AFR,"Crystal Structure of VDR-LBD/22S-Butyl-1a,24R-dihydroxyvitamin D3 complex",Rattus norvegicus,2.0,C 1 2 1,Monoclinic,153.448,43.394,41.992,90.0,95.341,90.0,"VAPOR DIFFUSION, HANGING DROP",41.34,23.29,78.75,55.46
3VT3,Crystal structures of rat VDR-LBD with R270L mutation,Rattus norvegicus,1.7,C 1 2 1,Monoclinic,153.883,41.626,41.956,90.0,96.31,90.0,"VAPOR DIFFUSION, HANGING DROP",32.05,12.44,76.91,64.47
1IE8,Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to KH1060,Homo sapiens,1.52,P 21 21 21,Orthorhombic,44.49,51.87,131.39,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",23.64,9.93,66.5,56.57
1IE9,Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to MC1288,Homo sapiens,1.4,P 21 21 21,Orthorhombic,44.94,51.42,132.52,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",15.67,6.39,50.78,44.39
3A3Z,Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277A(C23S),Homo sapiens,1.72,P 21 21 21,Orthorhombic,45.297,51.688,133.092,90.0,90.0,90.0,"VAPOR DIFFUSION, SITTING DROP",9.23,2.04,28.74,26.7
3A78,"Crystal structure of the human VDR ligand binding domain bound to the natural metabolite 1alpha,25-dihydroxy-3-epi-vitamin D3",Homo sapiens,1.9,P 21 21 21,Orthorhombic,44.889,51.12,132.196,90.0,90.0,90.0,"VAPOR DIFFUSION, SITTING DROP",13.04,4.89,56.8,51.91
3DR1,Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D receptor,Danio rerio,2.7,P 65 2 2,Hexagonal,66.1,66.1,265.6,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",49.0,20.36,90.91,70.55
4RUJ,Crystal structure of zVDR L337H mutant-VD complex,Danio rerio,2.352,P 65 2 2,Hexagonal,65.851,65.851,264.373,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",66.6,34.06,532.71,498.65
4RUP,Crystal structure of zVDR L337H mutant-Gemini72 complex,Danio rerio,2.75,P 65 2 2,Hexagonal,65.741,65.741,263.851,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",53.86,10.94,264.41,253.47
5NKY,Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain,Danio rerio,2.096,P 65 2 2,Hexagonal,66.191,66.191,261.698,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",56.23,31.12,103.91,72.79
5NMA,Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain,Danio rerio,2.8,P 65 2 2,Hexagonal,66.175,66.175,262.859,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",61.94,33.89,114.69,80.8
5NMB,Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain,Danio rerio,2.5,P 65 2 2,Hexagonal,65.893,65.893,262.598,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",,,,
5OW9,Vitamin D receptor complex,Danio rerio,2.403,P 65 2 2,Hexagonal,65.98,65.98,262.87,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",49.81,19.34,130.46,111.12
5OWD,Vitamin D receptor complex,Danio rerio,2.151,P 65 2 2,Hexagonal,65.75,65.75,262.97,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",56.12,30.08,146.95,116.87
6FO7,Vitamin D nuclear receptor complex 3,Danio rerio,2.59,P 65 2 2,Hexagonal,66.25,66.25,262.9,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",81.56,43.4,167.84,124.44
6FO8,Vitamin D nuclear receptor complex 4,Danio rerio,2.3,P 65 2 2,Hexagonal,66.69,66.69,264.52,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",66.31,31.13,133.09,101.96
6FO9,Vitamin D nuclear receptor complex 2,Danio rerio,2.701,P 65 2 2,Hexagonal,66.01,66.01,264.46,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",94.53,55.03,185.68,130.65
6FOB,Vitamin D receptor complex 5,Danio rerio,2.75,P 65 2 2,Hexagonal,66.22,66.22,264.2,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",80.33,39.95,164.28,124.33
6FOD,Vitamin D nuclear receptor complex 1,Danio rerio,2.5,P 65 2 2,Hexagonal,65.93,65.93,264.2,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",73.52,36.5,158.6,122.1
7B39,Allene-Based Design of a Noncalcemic Vitamin D Receptor Agonist,Danio rerio,2.13,P 65 2 2,Hexagonal,66.25,66.25,264.39,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",74.9,39.15,140.89,101.74
8CKC,"Vitamin D receptor complex with 25-amine derivative of 1,25D3",Danio rerio,2.1,P 65 2 2,Hexagonal,65.736,65.736,263.11,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",61.4,28.03,127.37,99.34
8P9W,vitamin D receptor complex with Xe4MeCF3 analog,Danio rerio,2.9,P 65 2 2,Hexagonal,65.82,65.82,263.22,90.0,90.0,120.0,"VAPOR DIFFUSION, SITTING DROP",86.68,30.0,188.66,158.66
5XPM,"Crystal structure of VDR-LBD complexed with 22S-Butyl-25RS-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin D3",Rattus norvegicus,2.2,C 1 2 1,Monoclinic,153.0,41.84,42.25,90.0,96.69,90.0,"VAPOR DIFFUSION, HANGING DROP",40.07,19.67,113.49,93.82
5XPN,"Crystal structure of VDR-LBD complexed with 25RS-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin D3",Rattus norvegicus,1.96,C 1 2 1,Monoclinic,153.74,43.16,42.03,90.0,95.32,90.0,"VAPOR DIFFUSION, HANGING DROP",35.37,17.31,99.97,82.66
5XPO,"Crystal structure of VDR-LBD complexed with 25-(hydroxyphenyl)-2-methylidene-19,26,27-trinor-25-oxo-1-hydroxyvitamin D3",Rattus norvegicus,2.28,C 1 2 1,Monoclinic,153.56,43.39,42.13,90.0,95.48,90.0,"VAPOR DIFFUSION, HANGING DROP",36.84,17.59,96.17,78.58
5XPP,"Crystal structure of VDR-LBD complexed with 25RS-(Hydroxyphenyl)-2-methylidene-19,26,27-trinor-1,25-dihydroxyvitamin D3",Rattus norvegicus,2.85,C 1 2 1,Monoclinic,154.38,42.86,41.74,90.0,95.65,90.0,"VAPOR DIFFUSION, HANGING DROP",42.59,22.05,103.99,81.94
5H1E,Interaction between vitamin D receptor and coactivator peptide SRC2-3,Rattus norvegicus,2.6,C 1 2 1,Monoclinic,155.77,42.88,42.21,90.0,95.83,90.0,"VAPOR DIFFUSION, HANGING DROP",42.74,30.36,62.08,31.72
3VTB,Crystal structure of rat vitamin D receptor bound to a partial agonist 25-adamantyl-23-yne-19-norvitammin D ADTK1,Rattus norvegicus,2.0,C 1 2 1,Monoclinic,153.563,43.199,42.487,90.0,95.56,90.0,"VAPOR DIFFUSION, HANGING DROP",52.8,22.65,100.65,78.0
3VTC,Crystal structure of rat vitamin D receptor bound to a partial agonist 26-adamantyl-23-yne-19-norvitammin D ADTK3,Rattus norvegicus,1.5,C 1 2 1,Monoclinic,126.847,45.733,46.638,90.0,93.87,90.0,"VAPOR DIFFUSION, HANGING DROP",15.78,6.77,59.96,53.19
3VTD,Crystal structure of rat vitamin D receptor bound to a partial agonist 26-adamantyl-23-yne-19-norvitammin D ADTK4,Rattus norvegicus,2.7,C 1 2 1,Monoclinic,153.178,43.897,42.526,90.0,95.73,90.0,"VAPOR DIFFUSION, HANGING DROP",49.74,22.68,93.83,71.15
2ZMH,Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism,Rattus norvegicus,2.1,C 1 2 1,Monoclinic,154.643,42.334,42.066,90.0,95.47,90.0,"VAPOR DIFFUSION, HANGING DROP",41.53,14.48,86.27,71.79
2ZMJ,Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism,Rattus norvegicus,2.35,C 1 2 1,Monoclinic,153.73,43.242,41.953,90.0,95.5,90.0,"VAPOR DIFFUSION, HANGING DROP",54.61,20.4,100.44,80.04
2ZXM,A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket,Rattus norvegicus,3.01,C 1 2 1,Monoclinic,153.252,43.424,42.369,90.0,95.97,90.0,"VAPOR DIFFUSION, HANGING DROP",48.2,25.04,77.88,52.84
2ZXN,A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket,Rattus norvegicus,2.1,C 1 2 1,Monoclinic,153.158,43.879,41.886,90.0,95.89,90.0,"VAPOR DIFFUSION, HANGING DROP",42.28,19.01,92.42,73.41
3WTQ,"Crystal structure of VDR-LBD complexed with 22S-butyl-2-methylidene-19-nor-1a,25-dihydroxyvitamin D3",Rattus norvegicus,2.1,C 1 2 1,Monoclinic,152.286,43.851,42.321,90.0,96.18,90.0,"VAPOR DIFFUSION, HANGING DROP",89.57,50.13,192.43,142.3
5B41,"Crystal structure of VDR-LBD complexed with 2-methylidene-19-nor-1a,25-dihydroxyvitamin D3",Rattus norvegicus,1.89,C 1 2 1,Monoclinic,154.17,41.75,41.77,90.0,96.02,90.0,"VAPOR DIFFUSION, HANGING DROP",37.6,16.65,122.87,106.22
5B5B,"Crystal structure of VDR-LBD complexed with 2-methylidene-26,27-diphenyl-19-nor-1,25-dihydroxyvitamin D3",Rattus norvegicus,2.0,C 1 2 1,Monoclinic,154.06,41.49,83.89,90.0,97.44,90.0,"VAPOR DIFFUSION, HANGING DROP",24.46,8.53,92.34,83.81
5GIC,Crystal structure of VDR in complex with DLAM-2P,Rattus norvegicus,2.352,C 1 2 1,Monoclinic,154.315,42.444,42.106,90.0,96.53,90.0,"VAPOR DIFFUSION, HANGING DROP",61.16,30.87,134.28,103.41
5GID,Crystal structure of VDR in complex with DLAM-4 (C2 form),Rattus norvegicus,2.151,C 1 2 1,Monoclinic,154.51,42.345,42.32,90.0,96.46,90.0,"VAPOR DIFFUSION, HANGING DROP",57.07,28.26,120.43,92.17
5GIE,Crystal structure of VDR in complex with DLAM-4P (P21 form),Rattus norvegicus,2.387,P 1 21 1,Monoclinic,65.364,42.077,96.802,90.0,94.55,90.0,"VAPOR DIFFUSION, HANGING DROP",44.93,17.32,89.69,72.37
5XUQ,"Crystal structure of VDR-LBD complexed with an antagonist, 2-methylidene-19,26,27-trinor-22-(S)-butyl-1-hydroxy-25-oxo-25-(1H-pyrrol-2-yl)- vitamin D3",Rattus norvegicus,2.8,C 1 2 1,Monoclinic,151.8,41.49,42.02,90.0,96.97,90.0,"VAPOR DIFFUSION, HANGING DROP",31.64,15.45,78.89,63.44
2ZMI,Crystal Structure of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs: Structural Basis for Vitamin D Receptor Antagonism and/or Partial Agonism,Rattus norvegicus,1.7,C 1 2 1,Monoclinic,155.222,42.412,41.955,90.0,95.21,90.0,"VAPOR DIFFUSION, HANGING DROP",27.97,12.67,71.01,58.34
2HC4,Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol,Danio rerio,2.2,P 65 2 2,Hexagonal,65.835,65.835,264.839,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",63.36,35.54,110.66,75.12
1DB1,CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D,Homo sapiens,1.8,P 21 21 21,Orthorhombic,45.193,52.443,133.286,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",31.17,17.93,59.64,41.71
4FHI,Development of synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition,Danio rerio,2.4,P 65 2 2,Hexagonal,66.3,66.3,264.509,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",61.62,35.12,98.59,63.47
2O4J,Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20Z and the NR2 Box of DRIP 205,Rattus norvegicus,1.74,C 1 2 1,Monoclinic,155.5,42.4,41.9,90.0,96.5,90.0,macroseeding in batch,25.28,11.83,53.79,41.96
2O4R,Crystal Structure of Rat Vitamin D Receptor Ligand Binding Domain Complexed with VitIII 17-20E and the NR2 Box of DRIP 205,Rattus norvegicus,1.98,C 1 2 1,Monoclinic,154.0,43.0,42.0,90.0,96.0,90.0,macroseeding in batch,26.08,12.21,62.66,50.45
4YNK,Crystal structure of vitamin D receptor ligand binding domain complexed with a 19-norvitamin D compound,Rattus norvegicus,2.3,C 1 2 1,Monoclinic,157.437,37.29,41.121,90.0,98.47,90.0,"VAPOR DIFFUSION, HANGING DROP",37.86,16.18,78.15,61.97
5AWJ,Crystal structure of VDR-LBD/partial agonist complex: 22S-hexyl analogue,Rattus norvegicus,2.2,C 1 2 1,Monoclinic,153.477,43.447,42.317,90.0,100.53,90.0,"VAPOR DIFFUSION, HANGING DROP",83.37,45.06,165.14,120.08
5AWK,Crystal structure of VDR-LBD/partial agonist complex: 22S-ethyl analogue,Rattus norvegicus,2.9,C 1 2 1,Monoclinic,154.03,41.97,41.86,90.0,95.96,90.0,"VAPOR DIFFUSION, HANGING DROP",89.07,62.54,165.3,102.76
5ZWE,Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having a vinyl ketone group via conjugate addition reaction,Rattus norvegicus,2.72,C 1 2 1,Monoclinic,153.53,42.44,41.87,90.0,95.98,90.0,"VAPOR DIFFUSION, HANGING DROP",41.27,27.05,76.67,49.62
5ZWF,Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having a enone with a beta methyl group via conjugate addition reaction,Rattus norvegicus,2.1,C 1 2 1,Monoclinic,153.56,41.73,42.02,90.0,96.22,90.0,"VAPOR DIFFUSION, HANGING DROP",36.02,23.38,70.67,47.29
5ZWH,Covalent bond formation between histidine of Vitamin D receptor (VDR) and a full agonist having an ene-ynone group via conjugate addition reaction,Rattus norvegicus,2.38,C 1 2 1,Monoclinic,154.3,42.52,41.96,90.0,95.72,90.0,"VAPOR DIFFUSION, HANGING DROP",42.03,21.25,77.3,56.05
5ZWI,Interaction between Vitamin D receptor (VDR) and a ligand having a dienone group,Rattus norvegicus,2.4,C 1 2 1,Monoclinic,153.67,42.4,41.85,90.0,95.96,90.0,"VAPOR DIFFUSION, HANGING DROP",38.48,23.97,76.44,52.47
6JEZ,Covalent labeling of rVDR-LBD by turn-on fluorescent probe mediated by conjugate addition and cyclization,Rattus norvegicus,2.3,C 1 2 1,Monoclinic,153.93,43.39,42.0,90.0,95.3,90.0,"VAPOR DIFFUSION, HANGING DROP",33.13,14.62,79.04,64.42
2ZFX,Crystal structure of the rat vitamin D receptor ligand binding domain complexed with YR301 and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,1.99,P 21 21 2,Orthorhombic,44.188,136.344,47.29,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",15.36,4.34,49.12,44.78
3A2H,Crystal structure of the rat vitamin D receptor ligand binding domain complexed with TEI-9647 and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,2.5,C 1 2 1,Monoclinic,124.809,45.349,46.662,90.0,100.13,90.0,"VAPOR DIFFUSION, HANGING DROP",27.43,10.09,54.72,44.63
3VRT,"VDR ligand binding domain in complex with 2-Mehylidene-19,25,26,27-tetranor-1alpha,24-dihydroxyvitaminD3",Rattus norvegicus,2.4,C 1 2 1,Monoclinic,152.988,43.867,42.428,90.0,95.94,90.0,"VAPOR DIFFUSION, HANGING DROP",78.27,32.89,161.98,129.09
3VRU,"VDR ligand binding domain in complex with 2-Methylidene-19,24-dinor-1alpha,25-dihydroxy vitaminD3",Rattus norvegicus,2.0,C 1 2 1,Monoclinic,154.34,42.29,42.21,90.0,95.89,90.0,"VAPOR DIFFUSION, HANGING DROP",37.67,17.94,76.66,58.72
3VRV,"VDR ligand binding domain in complex with 2-Methylidene-26,27-dimethyl-19,24-dinor-1alpha,25-dihydroxyvitamin D3",Rattus norvegicus,1.9,C 1 2 1,Monoclinic,154.14,42.77,42.12,90.0,95.42,90.0,"VAPOR DIFFUSION, HANGING DROP",36.25,16.83,80.62,63.79
3VRW,"VDR ligand binding domain in complex with 22S-Butyl-2-methylidene-26,27-dimethyl-19,24-dinor-1alpha,25-dihydroxyvitamin D3",Rattus norvegicus,2.4,C 1 2 1,Monoclinic,154.21,43.21,42.38,90.0,95.49,90.0,"VAPOR DIFFUSION, HANGING DROP",51.21,35.56,181.23,145.67
3VT7,Crystal structures of rat VDR-LBD with W282R mutation,Rattus norvegicus,1.65,C 1 2 1,Monoclinic,155.143,42.281,41.846,90.0,95.53,90.0,"VAPOR DIFFUSION, HANGING DROP",26.52,12.16,76.42,64.26
3W0G,Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands,Rattus norvegicus,1.94,C 1 2 1,Monoclinic,154.303,41.975,42.05,90.0,94.86,90.0,"VAPOR DIFFUSION, HANGING DROP",41.98,21.28,103.7,82.42
3W0H,Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands,Rattus norvegicus,1.8,C 1 2 1,Monoclinic,124.643,45.059,47.156,90.0,100.36,90.0,"VAPOR DIFFUSION, HANGING DROP",23.4,9.75,71.8,62.05
3W0I,Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,154.143,42.733,42.39,90.0,94.7,90.0,"VAPOR DIFFUSION, HANGING DROP",44.66,19.43,105.28,85.85
3W0J,Crystal Structure of Rat VDR Ligand Binding Domain in Complex with Novel Nonsecosteroidal Ligands,Rattus norvegicus,1.84,C 1 2 1,Monoclinic,154.214,42.39,42.144,90.0,94.89,90.0,"VAPOR DIFFUSION, HANGING DROP",38.17,18.98,73.87,54.89
3WT7,"Crystal structure of VDR-LBD complexed with 22R-Butyl-2-methylidene-26,27-dimethyl-19,24-dinor-1 ,25-dihydroxyvitamin D3",Rattus norvegicus,2.4,C 1 2 1,Monoclinic,128.21,44.31,45.81,90.0,93.56,90.0,"VAPOR DIFFUSION, HANGING DROP",38.47,19.25,101.23,81.98
5XZF,Vitamin D receptor with a synthetic ligand ADRO1,Rattus norvegicus,2.1,C 1 2 1,Monoclinic,154.07,41.11,41.42,90.0,96.42,90.0,"VAPOR DIFFUSION, HANGING DROP",43.63,23.78,107.7,83.92
5XZH,Vitamin D receptor with a synthetic ligand ADRO2,Rattus norvegicus,2.0,C 1 2 1,Monoclinic,153.665,41.763,42.01,90.0,95.58,90.0,"VAPOR DIFFUSION, HANGING DROP",50.64,28.98,118.61,89.63
6K5O,Development of Novel Lithocholic Acid Derivatives as Vitamin D Receptor Agonists,Rattus norvegicus,1.8,C 1 2 1,Monoclinic,153.884,43.69,41.792,90.0,96.05,90.0,"VAPOR DIFFUSION, HANGING DROP",43.23,23.98,98.44,74.46
7C7V,Vitamin D3 receptor/lithochoric acid derivative complex,Rattus norvegicus,2.0,C 1 2 1,Monoclinic,158.045,36.898,39.486,90.0,96.963,90.0,"VAPOR DIFFUSION, HANGING DROP",48.83,27.59,108.76,81.17
7C7W,Vitamin D3 receptor/lithochoric acid derivative complex,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,157.144,37.436,40.91,90.0,98.581,90.0,"VAPOR DIFFUSION, HANGING DROP",43.11,25.26,93.56,68.3
2HBH,Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain analog of calcitriol and SRC-1 peptide,Danio rerio,2.65,P 65 2 2,Hexagonal,65.682,65.682,265.096,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",59.61,17.61,138.84,121.23
2HCD,Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with Gemini and a coactivator peptide,Danio rerio,2.6,P 65 2 2,Hexagonal,65.859,65.859,265.018,90.0,90.0,120.0,"VAPOR DIFFUSION, HANGING DROP",62.46,31.93,98.25,66.32
1RJK,crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MD and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,1.99,C 1 2 1,Monoclinic,154.6,43.292,41.848,90.0,96.07,90.0,"VAPOR DIFFUSION, HANGING DROP",30.52,16.4,69.36,52.96
1RK3,"crystal structure of the rat vitamin D receptor ligand binding domain complexed with 1,25-dihydroxyvitamin D3 and a synthetic peptide containing the NR2 box of DRIP 205",Rattus norvegicus,2.2,C 1 2 1,Monoclinic,154.726,44.154,42.072,90.0,96.13,90.0,"VAPOR DIFFUSION, HANGING DROP",34.56,18.01,74.41,56.4
1RKG,crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2MbisP and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,154.447,44.114,41.86,90.0,96.62,90.0,"VAPOR DIFFUSION, HANGING DROP",30.46,16.85,69.44,52.59
1RKH,crystal structure of the rat vitamin D receptor ligand binding domain complexed with 2AM20R and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,2.28,C 1 2 1,Monoclinic,154.8,42.291,41.788,90.0,96.15,90.0,"VAPOR DIFFUSION, HANGING DROP",29.61,12.49,70.15,57.66
3VJS,Vitamin D receptor complex with a carborane compound,Rattus norvegicus,1.93,C 1 2 1,Monoclinic,154.605,43.292,42.085,90.0,95.28,90.0,"VAPOR DIFFUSION, HANGING DROP",43.03,21.97,80.04,58.07
3VJT,Vitamin D receptor complex with a carborane compound,Rattus norvegicus,2.0,C 1 2 1,Monoclinic,154.855,42.319,42.176,90.0,95.59,90.0,"VAPOR DIFFUSION, HANGING DROP",44.22,20.52,84.48,63.96
3W5P,Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,154.509,42.371,41.649,90.0,96.79,90.0,"VAPOR DIFFUSION, HANGING DROP",40.35,21.39,81.87,60.48
3W5Q,Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,153.799,42.339,41.546,90.0,96.38,90.0,"VAPOR DIFFUSION, HANGING DROP",43.19,23.47,85.72,62.25
3W5R,Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives,Rattus norvegicus,2.2,C 1 2 1,Monoclinic,154.433,42.026,41.514,90.0,96.25,90.0,"VAPOR DIFFUSION, HANGING DROP",51.82,25.26,100.54,75.28
3W5T,Crystal structure of complexes of vitamin D receptor ligand binding domain with lithocholic acid derivatives,Rattus norvegicus,2.29,C 1 2 1,Monoclinic,154.485,41.791,41.63,90.0,96.32,90.0,"VAPOR DIFFUSION, HANGING DROP",49.88,22.87,103.86,80.99
3WT5,A mixed population of antagonist and agonist binding conformers in a single crystal explains partial agonism against vitamin D receptor: Active vitamin D analogues with 22R-alkyl group,Rattus norvegicus,1.9,C 1 2 1,Monoclinic,127.84,44.81,46.06,90.0,93.57,90.0,"VAPOR DIFFUSION, HANGING DROP",28.14,11.36,106.13,94.77
3WT6,A mixed population of antagonist and agonist binding conformers in a single crystal explains partial agonism against vitamin D receptor: Active vitamin D analogues with 22R-alkyl group,Rattus norvegicus,2.0,C 1 2 1,Monoclinic,127.05,44.77,45.11,90.0,94.2,90.0,"VAPOR DIFFUSION, HANGING DROP",36.37,15.87,110.04,94.17
3AUN,Crystal structure of the rat vitamin D receptor ligand binding domain complexed with YR335 and a synthetic peptide containing the NR2 box of DRIP 205,Rattus norvegicus,1.81,P 21 21 2,Orthorhombic,44.237,136.521,47.334,90.0,90.0,90.0,"VAPOR DIFFUSION, HANGING DROP",13.26,4.1,44.45,40.35
7VQP,Vitamin D receptor complexed with a lithocholic acid derivative,Rattus norvegicus,1.94,C 1 2 1,Monoclinic,157.805,37.581,40.913,90.0,98.59,90.0,"VAPOR DIFFUSION, HANGING DROP",36.42,20.95,80.76,59.81
